Thermo Fisher Scientific Inc.

NYSE:TMO

Medical - Diagnostics & Research

Healthcare
$692.74 +0.96%

+$4.45 today

Market cap
$256.67B
Beta
0.87
P/E (TTM)
25.3
EPS (TTM)
$18.44
Dividend yield
0.39%
52W Low $390.50High $643.99

Volume 1.99M

Average 2.23M

TMO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Thermo Fisher Scientific Inc.NYSE: TMO

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin declines year over year

Q3 FY2026 selling, general & admin of $1.86B fell 13.8% year over year, behind the -3.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 2.4% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.

Context

  • Selling, general & admin amounted to 19.6% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 20 analysts of $9.57B (+9.6%) for the fiscal year ending Dec 2026, a step up from the +0.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.86B-2.4% QoQ
Last fiscal yearDec 2025
$8.73B+0.6% YoY
LTMSep 2026
$7.92B-3.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.8%+8.9%+22.7 pp
1 year+0.6%+9.6%+9.0 pp
3-year CAGR-1.1%+7.1%+8.1 pp
5-year CAGR+6.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
8.73B USD
Year-over-year change
+0.6%
4-year CAGR
+2.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How TMO compares with its peers on the latest reported figures

  • TMO's LTM Sep 2026 selling, general & admin of $7.92B is the 2nd highest of the 10 companies compared; the peer median is $970.7M.
  • Its year-over-year change of -3.4% is the lowest of 10, against a peer median of +4.1%.
  • Selling, general & admin amounts to 16.7% of revenue for TMO, versus a peer median of 27.9%.
TMO Competitors Peer median
Selling, General & Admin for TMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$8.12B +2.6%+4.9%31.7%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$7.92B -3.4%-1.1%16.7%
AAgilent Technologies, Inc.LTM Jul 2026$1.84B +9.9%+1.4%25.0%
WATWaters CorporationLTM Jul 2026$1.21B +68.4%+4.0%26.1%
MTDMettler-Toledo International Inc.LTM Jun 2026$1.03B +7.7%+2.1%24.9%
BRKRBruker CorporationLTM Jun 2026$970.7M +4.1%+15.9%27.7%
RVTYRevvity, Inc.LTM Jul 2026$942.58M +3.4%+7.6%32.4%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$847.8M +3.3%-0.3%32.7%
QGENQiagen N.V.LTM Jun 2026$586.14M +3.0%-1.1%27.9%
TECHBio-Techne CorporationLTM Sep 2026$469.88M +14.0%+8.7%38.3%
Peer median (excluding TMO) $970.7M+4.1%+4.0%27.9%

Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.21B44.92B42.86B42.88B44.56B
Cost of Revenue19.58B25.9B25.66B25.15B26.32B
Gross Profit19.63B19.01B17.19B17.73B18.24B
Gross Margin50.1%42.3%40.1%41.3%40.9%
Research & Development1.41B1.47B1.34B1.39B1.4B
Selling, General & Admin7.91B9.02B8.41B8.68B8.73B
Operating Expenses9.32B10.49B9.75B10.07B10.13B
Depreciation & Amortization2.59B3.38B3.41B3.11B2.78B
EBITDA11.97B11.94B11.2B11.8B11.47B
EBITDA Margin30.5%26.6%26.1%27.5%25.7%
Operating Income10.32B8.53B7.45B7.66B8.11B
Operating Margin26.3%19.0%17.4%17.9%18.2%
Interest Income43M272M879M1.08B993M
Interest Expense536M726M1.49B1.65B1.42B
Other Income / Expenses(1.48B)(862M)(1.21B)(667M)(842M)
Income Before Tax8.84B7.66B6.24B7B7.27B
Pre-Tax Margin22.5%17.1%14.6%16.3%16.3%
Income Tax Expense1.11B703M284M657M547M
Net Income7.73B6.95B6B6.34B6.74B
Net Margin19.7%15.5%14.0%14.8%15.1%
EPS (Basic)19.6117.7315.5316.5817.77
EPS (Diluted)19.4617.6415.4516.5317.74
Weighted Avg Shares394M392M386M382M376M
Weighted Avg Shares (Diluted)397M394M388M383M377M

Thermo Fisher Scientific Inc.

NYSE:TMO

Intrinsic Alpha fair value

Locked

Current Price

$692.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.